Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma

Acta Odontologica Scandinavica

Volumn 70, Issue 3, 2012, Pages 241-245

  Park, Jong Hwan ^a   Jeon, Do In ^b   Yoon, Hyo Eun ^b   Kwon, Seong Min ^b   Kim, Soo A ^c   Ahn, Sang Gun ^b   Yoon, Jung Hoon ^b  

^a Konyang University   (South Korea)

^b Chosun University   (South Korea)

^c Dongguk University   (South Korea)

Author keywords

Apoptosis; Oral sqaumous cell carcinoma; Paclitaxel; Poly I:C; Toll like receptor 3 (TLR3)

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METHODOLOGY; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOUTH NEOPLASMS; PACLITAXEL; POLY I-C; TOLL-LIKE RECEPTOR 3;

EID: 84859887762     PISSN: 00016357     EISSN: 15023850     Source Type: Journal    
DOI: 10.3109/00016357.2011.640278     Document Type: Article

References (21)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801. (Pubitemid 43261452)
2. Lee MS, Kim YJ. Signaling pathways downstream of patternrecognition receptors and their cross talk. Annu Rev Biochem 2007;76:447-80.
3. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161-7.
4. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9. (Pubitemid 46830615)
5. Killeen SD, Wang JH, Andrews EJ, RedmondHP. Exploitation of the Toll-like receptor system in cancer: A doubled-edged sword? Br J Cancer 2006;95:247-52. (Pubitemid 44187583)
6. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
7. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007;13:4565-74. (Pubitemid 47219727)
8. Pries R, Hogrefe L, Xie L, Frenzel H, Brocks C, Ditz C, et al. Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med 2008;21:209-15. (Pubitemid 351222854)
9. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: Past, present and future. Expert Rev Anticancer Ther 2006;6:1111-18. (Pubitemid 44203388)
10. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-16. (Pubitemid 38482067)
11. Hopper C, Kubler A, Lewis H, Tan IB, Putnam G. mTHPCmediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 2004;111:138-46. (Pubitemid 38859295)
12. Park JH, Yoon HE, Jeon DI, Ahn SG, Yoon JH. Activation of TLR2 and TLR5 did not affect tumor progression of an oral squamous cell carcinoma, YD-10B cells. J Oral Pathol Med 2010;39:781-5.
13. Lacour J, Laplanche A, Malafosse M, Gallot D, Julien M, Rotman N, et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: A 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 1992;18:599-604. (Pubitemid 23052271)
14. Laplanche A, Alzieu L, Delozier T, Berlie J, Veyret C, Fargeot P, et al. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapywithCMF in operable breast cancer: A 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res Treat 2000;64:189-91. (Pubitemid 32010336)
15. Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 2005;23:2374-8. (Pubitemid 40341487)
16. Jiang Q, Wei H, Tian Z. Poly I:C enhances cycloheximideinduced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008;8:12.
17. Hasan UA, Trinchieri G, Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem 2005;280:20620-7. (Pubitemid 40776765)
18. Scarim AL, Arnush M, Blair LA, Concepcion J, Heitmeier MR, Scheuner D, et al. Mechanisms of beta-cell death in response to double-stranded (ds) RNA and interferon-gamma: DsRNA-dependent protein kinase apoptosis and nitric oxide-dependent necrosis. Am J Pathol 2001;159:273-83. (Pubitemid 33704212)
19. Robbins MA, Maksumova L, Pocock E, Chantler JK. Nuclear factor-kappaB translocation mediates double-stranded ribonucleic acid-inducedNIT-1beta-cell apoptosisandup-regulates caspase-12 and tumor necrosis factor receptor-associated ligand (TRAIL). Endocrinology 2003;144:4616-25. (Pubitemid 37204861)
20. Kaiser WJ, Kaufman JL, Offermann MK. IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J Immunol 2004;172: 1699-710. (Pubitemid 38116818)
21. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, et al. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci 2010; 101:1610-17.